 The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis CF lung disease. Study drug will be administered through a nebulizer a device that delivers medication as a mist by breathing it in. 